Quantification of E-Cadherin Methylation in Plasma Circulating DNA Isolated from Gastric Cancer Patients Using Fe3O4 Magnetic Nanoparticles

2016 ◽  
Vol 8 (12) ◽  
pp. 1099-1105
Author(s):  
Zhiyang Li ◽  
Zhongsi Chen ◽  
Senqing Chen ◽  
Guojian Ma ◽  
Xiaomei Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Magnetic Nanoparticles ◽  
Cancer Patients ◽  
Circulating Dna ◽  
Gastric Cancer Patients ◽  
E Cadherin

scholarly journals E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients

2004 ◽  
Vol 40 (12) ◽  
pp. 1897-1903 ◽  
Author(s):  
Carla Oliveira ◽  
Paulo Ferreira ◽  
Sérgio Nabais ◽  
Luisa Campos ◽  
Ana Ferreira ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Genetic Predisposition ◽  
Germline Mutations ◽  
Gastric Cancer Patients ◽  
E Cadherin

Influence of age on soluble E-cadherin serum levels prevents its utility as a disease marker in gastric cancer patients

2008 ◽  
Vol 43 (6) ◽  
pp. 765-766 ◽  
Author(s):  
Corrado Pedrazzani ◽  
Stefano Caruso ◽  
Giovanni Corso ◽  
Daniele Marrelli ◽  
Alessandro Neri ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Disease Marker ◽  
Gastric Cancer Patients ◽  
E Cadherin

Circulating DNA in the Blood of Gastric Cancer Patients

2008 ◽  
Vol 1137 (1) ◽  
pp. 226-231 ◽  
Author(s):  
Elena V. Kolesnikova ◽  
Svetlana N. Tamkovich ◽  
Olga E. Bryzgunova ◽  
Petr I. Shelestyuk ◽  
Valentina I. Permyakova ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Circulating Dna ◽  
Gastric Cancer Patients

scholarly journals Loss ofLLGL1Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Alexander Desuki ◽  
Frank Staib ◽  
Ines Gockel ◽  
Markus Moehler ◽  
Hauke Lang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Cell Lines ◽  
Gastric Cancer Cell ◽  
Cellular Adhesion ◽  
Peritoneal Metastases ◽  
Diffuse Gastric Cancer ◽  
Gastric Cancer Patients ◽  
E Cadherin

Background. Loss ofLLGL1has been associated with loss of cellular adhesion and dissemination of cells from colorectal cancer and malignant melanoma. Regulation and relevance ofLLGL1were analyzed in gastric cancer patients with lymphatic and distant dissemination. Furthermore,LLGL1expression was analyzed in relation to the cellular adhesion proteinE-cadherin.Methods.LLGL1andE-cadherintranscription levels were evaluated in 56 gastric cancer patients and five gastric cancer cell lines. IHC staining forLLGL1was performed on 39 gastric cancer specimens.LLGL1was stably transfected intoLLGL1negative gastric cancer cell line SNU16 (del(17) (p11.2)) for functionalin vitroassays and a xenograft bioassay.Results. Gastric cancer specimens and cell lines displayedLLGL1andE-cadherinexpression levels with variable intensity. In gastric mucosa,LLGL1exhibited weak cytoplasmic and strong cortical staining. Loss ofLLGL1expression occurred in 65% of gastric cancers and significantly correlated with loss ofE-cadherinexpression (P=0.00009). Loss ofLLGL1expression was associated with the diffuse type of gastric cancer (P=0.029) with peritoneal carcinomatosis (M1; P=0.006) and with female gender (P=0.017). Stable reexpression ofLLGL1in SNU16 cells significantly increased both plastic surface adhesion and extracellular matrix proteins laminin and fibronectin, but had no impact onin vitroproliferation, apoptosis, or invasion or onin vivoproliferation or differentiation in our xenograft bioassay.Conclusion.LLGL1is coexpressed withE-cadherin.Loss of expression of either protein is associated with diffuse gastric cancer and peritoneal metastases.LLGL1does not impact on proliferation or epithelial-mesenchymal transition (EMT) rather increasing cellular adhesion.

scholarly journals A Clinical Study of Serum E-cadherin Values in Gastric Cancer Patients

1995 ◽  
Vol 28 (3) ◽  
pp. 750-750
Author(s):  
Yoshihide Shino ◽  
Akihiko Watanabe ◽  
Yukishige Yamada ◽  
Jun Yamashita ◽  
Masahiko Matsuda ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Study ◽  
Cancer Patients ◽  
Gastric Cancer Patients ◽  
E Cadherin

scholarly journals Germline mutations of E-cadherin gene in Korean familial gastric cancer patients

1999 ◽  
Vol 44 (3) ◽  
pp. 177-180 ◽  
Author(s):  
Kyong-Ah Yoon ◽  
J.-L. Ku ◽  
Han-Kwang Yang ◽  
Woo Ho Kim ◽  
Suk Young Park ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Germline Mutations ◽  
Familial Gastric Cancer ◽  
Gastric Cancer Patients ◽  
E Cadherin

scholarly journals Characterization of soluble E-cadherin as a disease marker in gastric cancer patients

1998 ◽  
Vol 78 (8) ◽  
pp. 1095-1101 ◽  
Author(s):  
J Gofuku ◽  
H Shiozaki ◽  
Y Doki ◽  
M Inoue ◽  
M Hirao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Disease Marker ◽  
Gastric Cancer Patients ◽  
E Cadherin

scholarly journals Soluble e-cadherin as a diagnostic and prognostic marker in gastric carcinoma

Folia Medica ◽  
2013 ◽  
Vol 55 (3-4) ◽  
pp. 26-32 ◽  
Author(s):  
Christos Tsalikidis ◽  
Fotini Papachristou ◽  
Michael Pitiakoudis ◽  
Byron Asimakopoulos ◽  
Grigorios Trypsianis ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Regression Analysis ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Linear Regression Analysis ◽  
Clinicopathological Parameters ◽  
Multivariate Linear Regression Analysis ◽  
Cox Regression Analysis ◽  
Gastric Cancer Patients ◽  
E Cadherin

ABSTRACT OBJECTIVE: Modifications in E-cadherin (E-Cad) expression are associated with dedifferentiation, progression, metastases and poor prognosis in many types of tumors. The aim of the present study was to identify a potential association of the pre- and post-operative soluble E-Cad levels (sE-Cad) with the clinicopathological parameters of patients with gastric cancer. PATIENTS AND METHODS: Serum sE-Cad levels were determined in 99 gastric cancer patients and 78 healthy volunteers using ELISA. RESULTS: Levels of sE-Cad were significantly increased in gastric cancer patients compared with these levels in healthy controls (p < 0.001). For the evaluation of the diagnostic significance of sE-Cad the area under the receiver operating characteristic (ROC) curve (AUC) was 0.835, while the optimal cut-off point of 9.9 μg/mL was determined to classify gastric cancer patients, which yielded sensitivity of 72.7%, specificity of 80.8% and accuracy of 76.3%. Poor differentiation (p = 0.009) and the presence of distant metastases (p < 0.001) were the two significant independent prognostic determinants for high sE-Cad levels in multivariate linear regression analysis. The preoperative levels of sE-Cad also proved helpful in classifying patients according to the choice treatment (curative versus palliative) (AUC, 0.656); when the optimal cut-off point was set at 17.60 μg/mL, the sensitivity was 57%, the specificity was 83% and accuracy was 75%. Survival was shorter in patients with increased sE-Cad (median, 7 months vs 39 months, p = 0.0002), although multivariate Cox regression analysis demonstrated a marginal prognostic significance of sE-Cad for survival (adjusted HR = 1.68, 95% CI = 0.93 to 3.02, p = 0.072). CONCLUSIONS: Serum sE-Cad levels could be considered as a diagnostic and prognostic marker in gastric cancer patients as well as a tool to select a treatment approach. The prognostic value of sE-Cad on overall survival requires further study.

Sign in / Sign up

Export Citation Format

Share Document